GUANGZHOU, China, April 1, 2026 /PRNewswire/ — XPeng Inc. (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading global AI mobility technology company, today announced its vehicle delivery results for March and the first quarter of 2026.
In March 2026, XPENG delivered a total of 27,415 vehicles, representing an 80% increase over the prior month. In the first quarter of 2026, XPENG delivered 62,682 vehicles.
On March 25, 2026, XPENG introduced a three-year strategy for Latin America and officially entered the Mexican market, marking a major milestone in its global expansion. Under this strategy, the Company plans to launch both pure electric and range-extended electric models in 2027, laying the groundwork for broader market coverage and targeting a leading position in the region by 2028.
About XPENG
XPENG is a leading Chinese Smart EV company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers. Its mission is to become a smart technology company trusted and loved by users worldwide. In order to optimize its customers’ mobility experience, XPENG develops in-house its full-stack advanced driver-assistance system technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrical/electronic architecture. XPENG is headquartered in Guangzhou, China, with main offices in Beijing, Shanghai, Shenzhen, Silicon Valley and San Diego. The Company’s Smart EVs are mainly manufactured at its plants in Zhaoqing and Guangzhou, Guangdong province. For more information, please visit https://www.xpeng.com/.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Statements that are not historical facts, including statements about XPENG’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: XPENG’s goal and strategies; XPENG’s expansion plans; XPENG’s future business development, financial condition and results of operations; the trends in, and size of, China’s EV market; XPENG’s expectations regarding demand for, and market acceptance of, its products and services; XPENG’s expectations regarding its relationships with customers, suppliers, third-party service providers, strategic partners and other stakeholders; general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in XPENG’s filings with the United States Securities and Exchange Commission. All information provided in this announcement is as of the date of this announcement, and XPENG does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Contacts:
For Investor Enquiries:
IR Department
XPeng Inc.
Email: [email protected]
Jenny Cai
Piacente Financial Communications
Tel: +1 212 481 2050 / +86 10 6508 0677
Email: [email protected]
For Media Enquiries:
PR Department
XPeng Inc.
Email: [email protected]
ข่าวที่เกี่ยวข้อง
- Xinhua Silk Road: งานแข่งขันการพัฒนาและนวัตกรรม “Smart City” ปิดฉากลงที่กว่างซี ทางตอนใต้ของจีน โดยมีผลงานที่ได้รับรางวัล 252 ชิ้น
- YFPA Successfully Hosts Inaugural Financial Education Forum Over 170 Participants Join to Promote Financial Literacy Across the Community
- Xinhua Silk Road: คณะผู้แทนจากเมืองเสียนหยางเยือนสถานทูต 5 ประเทศในกรุงปักกิ่ง เดินหน้าส่งเสริมวัฒนธรรมชาจีนสู่เวทีโลก
- NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient
